CTMX FY 2016 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

FY 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M+95.1% YoY

Gross Profit

$15M100.0% margin

Operating Income

-$60M-396.1% margin

Net Income

-$59M-391.5% margin

EPS (Diluted)

$-1.63

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$4M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$199M

Total Liabilities

$121M

Stockholders' Equity

$78M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$8M	+95.1%
Gross Profit	$15M	$8M	+95.1%
Operating Income	-$60M	-$33M	-79.5%
Net Income	-$59M	-$35M	-66.5%